Last updated: 17 July 2019 at 8:22am EST

Robert Silverman Net Worth




The estimated Net Worth of Robert Silverman is at least $709 Thousand dollars as of 9 March 2017. Robert Silverman owns over 30,966 units of Concert Pharmaceuticals Inc stock worth over $427,498 and over the last 10 years Robert sold CNCE stock worth over $281,750.

Robert Silverman CNCE stock SEC Form 4 insiders trading

Robert has made over 9 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Robert exercised 30,966 units of CNCE stock worth $34,992 on 9 March 2017.

The largest trade Robert's ever made was exercising 30,966 units of Concert Pharmaceuticals Inc stock on 9 March 2017 worth over $34,992. On average, Robert trades about 7,244 units every 78 days since 2014. As of 9 March 2017 Robert still owns at least 51,075 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Robert Silverman stock trades at the bottom of the page.



What's Robert Silverman's mailing address?

Robert's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, SUITE 500, LEXINGTON, MA, 02421.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.



What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.



What does Concert Pharmaceuticals Inc's logo look like?

Concert Pharmaceuticals Inc logo

Complete history of Robert Silverman stock trades at Concert Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
9 Mar 2017 Robert Silverman
Senior VP and General Counsel
Option 30,966 $1.13 $34,992
9 Mar 2017
51,075
20 Jan 2016 Robert Silverman
Senior VP and General Counsel
Option 8,000 $1.13 $9,040
20 Jan 2016
21,415
20 Jan 2016 Robert Silverman
Senior VP and General Counsel
Option 8,000 $1.13 $9,040
20 Jan 2016
21,415
9 Nov 2015 Robert Silverman
Senior VP and General Counsel
Option 3,600 $1.13 $4,068
9 Nov 2015
13,600
9 Nov 2015 Robert Silverman
Senior VP and General Counsel
Option 3,600 $1.13 $4,068
9 Nov 2015
13,600
18 Sep 2015 Robert Silverman
Senior VP and General Counsel
Sale 10,000 $20.00 $200,000
18 Sep 2015
10,000
8 Jun 2015 Robert Silverman
Senior VP and General Counsel
Sale 5,000 $16.35 $81,750
8 Jun 2015
15,000
11 Mar 2015 Robert Silverman
Senior VP and General Counsel
Option 5,000 $1.13 $5,650
11 Mar 2015
25,000
29 May 2014 Robert Silverman
Senior VP and General Counsel
Option 20,000 $1.13 $22,600
29 May 2014
20,000


Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: